Comment from Alliance for Pharmacy Compounding
AnonymousOtherAdvocacy
Summary: The Alliance for Pharmacy Compounding is requesting that the FDA provide more transparency regarding the process and specific safety risks used to determine which substances were added to Category 2. They argue that this information is necessary to help educate stakeholders and to prevent patients from seeking riskier, non-pharmacy versions of these substances.
See attached file for letter from the Alliance for Pharmacy Compounding request to the FDA regarding Category 2 additions.